课题基金 / 基金详情

GPIb Alpha-VWF-A1 bond kinetics in health and disease

GPIb Alpha-VWF-A1 bond kinetics in health and disease
健康和疾病中的 GPIb Alpha-VWF-A1 键动力学
批准号:
8497711
负责人:
Thomas G Diacovo
金额:
$37.93万
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-08-15 至 2015-04-30
关键词:
AccountingAcuteAddressAdhesionsAnimal ModelAnimalsAntibodiesBindingBiologicalBiological AssayBiological ModelsBiological ProcessBiomedical EngineeringBiophysicsBiotinylationBleeding time procedureBlood CirculationBlood ClotBlood PlateletsBlood VesselsBlood coagulationBone MarrowCell AdhesionCell Adhesion MoleculesCell Culture SystemChemicalsCleaved cellCollaborationsCollagenComplexCoronaryDefectDevelopmentDiseaseDissociationEffectivenessEventFoundationsGenerationsGenetic Predisposition to DiseaseGenetically Modified AnimalsGleanHealthHemorrhageHemostatic functionHumanIn VitroIndividualInduced MutationInflammationInjection of therapeutic agentInjuryInsertion MutationKineticsKnowledgeLaboratoriesLeadLengthLigandsLightMassachusettsMechanicsMegakaryocytesMetalloproteasesMicroscopyMinorModelingMolecularMusMutant Strains MiceMutationPatientsPatternPharmaceutical PreparationsPhenotypePlasmaPlatelet Count measurementPlatelet aggregationPlayPositioning AttributePreclinical TestingProceduresProcessProductionPropertyProtein FragmentProteolysisRecombinant ProteinsRecombinantsResearchResolutionRoleSimulateSiteSite-Directed MutagenesisSolutionsSpectrum AnalysisStructure-Activity RelationshipSurfaceSyndromeSystemTechniquesTertiary Protein StructureTestingTherapeuticTherapeutic AgentsThrombocytopeniaThrombosisThrombusTimeValue of LifeVideo Microscopyactivator 1 proteinanalogangiogenesisaptamerarteriolebasecerebrovasculardesigndrug testingembryonic stem cellgain of function mutationhuman diseasein vitro Assayin vivoinjuredinsightintravital microscopymedical schoolsmouse modelmutantpreventprotein protein interactionpublic health relevancereceptorresponsespecies differencetherapy designtoolvon Willebrand Factor

项目摘要

项目成果

Thomas G Diacovo的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请方提供):动物模型是研究止血和血栓形成的分子机制和遗传易感性的重要实验工具。特别是,小鼠缺乏GPIb 1或VWF提供了相当大的洞察力,这种受体-配体对的重要性,不仅在形成血栓,但在血小板的发展,血栓前疾病状态,炎症和血管生成。也就是说,这些模型是有限的,因为没有信息可以收集到它们的结构-功能关系,也不能评估专门设计用于破坏人类这种相互作用的治疗剂的体内有效性。为此,我们现在将几个实验室的知识和专业知识应用于:1)对GPIba-VWF-A1键进行详细的生物物理分析,以了解这种相互作用的物理化学性质如何调节健康和疾病中的血小板-血管性血友病因子(VWF)相互作用,2)通过产生和研究在这种相互作用的机械和/或动力学特性中具有特定改变的动物来验证所提出的生物物理机制,和3)利用这些知识开发生物平台来测试旨在专门抑制人类这种相互作用的疗法。我们相信,通过采取这种全面的方法,我们将避免与GPIba-VWF-A1相互作用中潜在的物种差异相关的陷阱。
英文摘要
DESCRIPTION (provided by applicant): Animal models are important experimental tools for investigating the molecular mechanisms and genetic susceptibilities underlying hemostasis and thrombosis. In particular, mice deficient in GPIb1 or VWF have provided considerable insight into the importance of this receptor-ligand pair not only in the formation of blood clots but in platelet development, prothrombotic disease states, inflammation, and angiogenesis. That said these models are limited as no information can be gleaned on their structure-function relationship nor can one assess the in vivo effectiveness of therapeutic agents specifically designed to disrupt this interaction in humans. To this end, we now apply the knowledge and expertise of several laboratories to: 1) perform a detailed biophysical analysis of the GPIba-VWF-A1 bond in order to understand how the physicochemical properties of this interaction may regulate platelet-von Willebrand Factor (VWF) interactions in health and disease, 2) validate proposed biophysical mechanisms by generating and studying animals with specific alterations in mechanical and/or kinetic properties of this interaction, and 3) exploit this knowledge to develop biological platforms to test therapies designed to specifically inhibit this interaction in humans. We believe that by taking this comprehensive approach, we will avoid pitfalls related to potential species differences in GPIba-VWF-A1 interactions.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Targeting the Thromboinflammatory Response to Mitigate Bowel Injury in Necrotizing Enterocolitis
Targeting non-classical oncogenes as therapy for T-ALL
Targeting non-classical oncogenes as therapy for T-ALL
Targeting non-classical oncogenes as therapy for T-ALL
海外基金